Tocilizumab for severe chest crisis in sickle cell disease
Part of Blood & lymphatic, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sickle cell disease of any type (like SS, SC, or S-beta thalassemia).
- You are at least 2 years old.
- You are in the hospital for acute chest syndrome (fever and/or breathing problems with a new finding on a chest X-ray or CT scan).
- You need extra oxygen (at least 2 liters per minute) or a breathing machine for less than 48 hours.
- If you are a woman who can become pregnant, you must have a negative pregnancy test and use effective birth control for 3 months after treatment.
- You must not have certain other serious infections or have taken certain other medicines recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a fast, goal-based red blood cell exchange (a filter treatment) for people with sickle cell disease who develop severe acute chest syndrome and need extra oxygen. The goal is to see if starting it early helps recovery.
This trial tests if lying on your stomach while awake can help people with sickle cell disease who are in intensive care for severe acute chest syndrome. It may improve breathing and reduce the need for a ventilator.
This trial tests a new gene therapy for sickle cell disease. It uses your own blood stem cells (collected from bone marrow) that are modified in a lab to help produce healthy red blood cells, then given back to you after a short chemotherapy. The goal is to reduce or stop severe complications like pain crises and lung problems.
This trial studies tocilizumab (a medicine that calms inflammation) to treat acute chest syndrome in people with sickle cell disease. It may help improve symptoms and recovery by targeting key immune signals involved in this complication.
This early trial tests crizanlizumab (a medicine for sickle cell) to see if it improves how your body matches oxygen supply with oxygen needs. It may be helpful for reducing sickle-cell–related complications by changing blood vessel and oxygen behavior.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.